Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response
- Cell Death Dis. 2023 Aug 26;14(8):561. doi: 10.1038/s41419-023-06055-w.
- 1. Department of Internal Medicine 5, Haematology and Oncology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), Erlangen, Germany.
- 2. Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
- 3. Deptartment of Pediatrics and Adolescent Medicine, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), Erlangen, Germany.
- 4. Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
- 5. Department of Internal Medicine 5, Haematology and Oncology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), Erlangen, Germany. [email protected].
- 6. Bavarian Cancer Research Center (BZKF), Erlangen, Germany. [email protected].
Cellular stress responses including the unfolded protein response (UPR) decide over the fate of an individual cell to ensure survival of the entire organism. During physiologic UPR counter-regulation, protective proteins are upregulated to prevent cell death. A similar strategy induces resistance to UPR in Cancer. Therefore, we hypothesized that blocking protein synthesis following induction of UPR substantially enhances drug-induced Apoptosis of malignant cells. In line, upregulation of the chaperone BiP was prevented by simultaneous arrest of protein synthesis in B cell malignancies. Cytotoxicity by immunotoxins-approved inhibitors of protein synthesis-was synergistically enhanced in combination with UPR-inducers in seven distinct hematologic and three solid tumor entities in vitro. Synergistic cell death depended on mitochondrial outer membrane permeabilization via Bak/Bax, which correlated with synergistic, IRE1α-dependent reduction of BID, accompanied by an additive fall of Mcl-1. The strong synergy was reproduced in vivo against xenograft mouse models of mantle cell lymphoma, Burkitt's lymphoma, and patient-derived acute lymphoblastic leukemia. In contrast, synergy was absent in blood cells of healthy donors suggesting a tumor-specific vulnerability. Together, these data support clinical evaluation of blocking stress response counter-regulation using inhibitors of protein synthesis as a novel therapeutic strategy.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Proteasome; NF-κB; Apoptosis; Autophagy; TREM receptor; Ligands for Target Protein for PROTACResearch Areas: Cancer
-
target: Fluorescent DyeResearch Areas: Others
-
-
target: IRE1
-